Omeros Corporation (3O8.F)
| Previous close | 3.2260 |
| Open | 3.2660 |
| Bid | 0.0000 x 33800 |
| Ask | 0.0000 x 33100 |
| Day's range | 3.1360 - 3.2660 |
| 52-week range | 0.9770 - 7.0950 |
| Volume | |
| Avg. volume | 34 |
| Market cap | 186.6M |
| Beta (5Y monthly) | 1.33 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.6000 |
| Earnings date | 13 May 2024 - 16 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 34.63 |
Business WireOmeros Corporation to Announce First Quarter Financial Results on May 15, 2024
SEATTLE, May 10, 2024--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter and year ended March 31, 2024, on Wednesday, May 15, 2024, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.
Business WireOmeros Corporation Announces Upcoming Presentations at 2024 European Hematology Association (EHA) Hybrid Congress
SEATTLE, May 09, 2024--Omeros Corporation (Nasdaq: OMER) today announced that interim analysis data from its ongoing Phase 2 study of OMS906 in patients with paroxysmal nocturnal hemoglobinuria submitted to the 2024 European Hematology Association (EHA) Hybrid Congress has been selected for podium presentation. The EHA Congress will be held June 13-16, 2024, in Madrid, Spain. OMS906 is Omeros’ investigational inhibitor of MASP-3 targeting the alternative pathway of complement. Two additional pos
